Biotech News
Related news
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
VIRIVirios Therapeutics2026-07-20 12:30 EST
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
SCYXSCYNEXIS2026-09-28 11:30 EST
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
ABUSArbutus2026-10-01 11:30 EST
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-09-30 11:30 EST
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
SPROSpero Therapeutics2026-07-14 11:02 EST
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
ANTXAN2 Therapeutics2026-11-04 12:00 EST
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
Atea
Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...
Recent company news
AVIRAtea2026-11-09 21:05 EST
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
AVIRAtea2026-11-09 12:00 EST
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
AVIRAtea2026-11-02 21:05 EST
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
AVIRAtea2026-09-08 11:00 EST
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
AVIRAtea2026-08-12 20:05 EST
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Stock data
- Close
- 3.93 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
